Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on SHAFTESBURY PLC. We currently have 18 research reports from 2 professional analysts.
|09Mar17 12:41||RNS||Holding(s) in Company|
|07Mar17 16:02||RNS||Director/PDMR Shareholding|
|02Mar17 14:32||RNS||Holding(s) in Company|
|27Feb17 16:46||RNS||Notice of Results|
|10Feb17 14:15||RNS||Result of AGM|
|10Feb17 07:00||RNS||Finance and trading update|
|09Feb17 12:19||RNS||Holding(s) in Company|
Frequency of research reports
Research reports on
Panmure Morning Note 05-02-16
05 Feb 16
The trading update this morning confirms that Shaftesbury's central London villages remain a major tourist attraction for London. The group curates the portfolio well so that streets become destinations with a unique character. The portfolio could not be replicated and positioned with excellent access to transport and the new Crossrail stations, footfall will continue to be amongst the highest in the UK. This will continue to drive demand and push up rents, which remain attractive compared to Regent Street, Oxford Street and Covent Garden. We think that the current weakness provides investors with an excellent opportunity to add to positions. We retain our BUY recommendation and 1106p target price (10% premium to one year forward NAV).
Panmure Morning Note 24-11-15
24 Nov 15
Shaftesbury continually delivers a strong and consistent performance. The group benefits from its Central London focus so that its c600 shops, restaurants and bars enjoy footfall of 40m-50m pa creating a vibrancy which is hard to beat globally and strong demand for its premises. The model is well articulated, established and diligently executed. These results should please the market as they beat consensus for NAV/s, which rose 21.9% to 869p. The outlook remains positive, underpinned by domestic growth in retail sales and high tourist footfall. Shaftesbury is our conviction Buy with a target valuation of 1106p.
Panmure Research - Conviction List Q4 2015 01-10-15
01 Oct 15
9.2% outperformance in Q3 sounds good, but set against a market that fell 9.1% this is hardly a great result. The disparity of performance was enormous with a couple of true mistakes in the Mining and Oil & Gas sector taking a heavy toll. For Q4 we have cut some losses and introduced Greene King, Microfocus and Wentworth on the Long calls with two new high conviction Short calls in Rolls Royce and Majestic Wine. Total outperformance since 2010 is 114% with 2 negative quarters out of 28. It seems there may be some alpha in our analyst's stock knowledge.
Panmure Morning Note 30-09-15
30 Sep 15
Shaftesbury has released a short trading update today highlighting progress with two major schemes and the continued strong trading conditions for its tenants in the core west end of London. We look forward to the results due 11 November 2015 which we anticipate will be strong with an estimated 16.3% rise in NAV/s to 830p. We continue to believe that the shares are undervalued since the estate value does not reflect the unique portfolio which could not be replicated in the heart of London. We retain our BUY recommendation and 1106p target price.
Another positive verdict
20 Mar 17
Burford’s results for 2016 produced another outstanding set of figures. Revenue grew by 60% to $163.4m with strong growth in the litigation finance business and an additional boost from a secondary sale in the Petersen case. On an underlying basis net income grew to $114m, a 75% increase despite the investment in growing capacity which increased costs. A combination of ongoing investment and gains and increases on valuation saw the fair value of the litigation assets increase 67% to $559m, underpinned by a growth in invested capital to $394m. With the results statement there was an announcement of a further sale of 9% of the Petersen case at a valuation of 20 times the cost of investment.
N+1 Singer - Morning Song 22-03-2017
22 Mar 17
Carador Income Fund (CIFU LN) Premium rating restored, high levels of refinancing activity | Cello Group (CLL LN) Outlook getting brighter – watch Pulsar | Eckoh (ECK LN) Largest ever US secure payments win | eg solutions (EGS LN) Full year results in line | Futura Medical (FUM LN) Licensing deal for CSD500 in Portugal | Verona Pharma (VRP LN) Global agreement with QuintilesIMS to support development of RPL554 | Xaar (XAR LN) 2016 results slightly ahead, reduced visibility in 2017
Small Cap Breakfast
23 Mar 17
K3 Capital Group—Schedule 1 from the Group of business and company sales specialists across business transfer, business brokerage and corporate finance. Admission date and fundraise details TBC. Integumen— Schedule 1 from the personal health company developing and commercialising technology and products for the human integumentary system. Raising £2.16m at 5p. Expected market cap £8.16m. Admission expected 5 April. Sentinel—Investment company expecting NEX admission/introduction on 24 March. £636k raised pre-IPO. BioPharma Credit—Expected Gross Initial Acquisition Proceeds now c.$338m. Gross Cash Proceeds capped at $423m with placing and open offer. Results expected 23 March with admission now due 30 march.
Small Cap Breakfast
21 Mar 17
First Sentinel—Investment company expecting NEX admission/introduction on 24 March. £636k raised pre-IPO. BioPharma Credit—Expected Gross Initial Acquisition Proceeds now c.$338m. Gross Cash Proceeds capped at $423m with placing and open offer. Results expected 23 March with admission now due 30 march. Tufton Oceanic Assets- The Company intends to invest in a diversified portfolio of second hand commercial sea-going vessels where the Investment Manager believes that an attractive opportunity exists in shipping. $150m raise. Admission 3 April.
N+1 Singer - Morning Song 23-03-2017
23 Mar 17
eg solutions (EGS LN) Re-focusing on sales is delivering rewards | Futura Medical (FUM LN) FY results: continued clinical, regulatory and commercial progress | Halfords Group (HFD LN) Confidence in FX mitigation grows; stay at BUY | IFG Group (IFP LN) Top line growth but earnings pressures remain | Realm Therapeutics (RLM LN) FY results in line; on track for Phase II start in 2017 | Safestyle UK (SFE LN) Another good full year performance but valuation up with events | WYG (WYG LN) Mixed conclusion to FY17, reassuring FY18 outlook